Our unwavering goal is to create, develop, and commercialize new medicines that meaningfully enhance patient care—starting with the patient in mind from the very beginning of our drug design process.
Our DCE Platform® has very broad potential across numerous therapeutic areas. Because medicines for diseases are used continually by patients, the impact may be significant for enhancing clinical safety, tolerability or efficacy with Concert’s deuterium-modified medicines.
We have implemented our DCE Platform—in our proprietary drug programs and in our collaborations—to develop innovative medicines that offer improved ways to target a range of disease areas including CNS disorders, renal disease, inflammation and cancer.
Representative Diseases with Drug Development Approaches Using Concert’s DCE Platform
Therapeutic Applications for Concert’s Proprietary Programs
About Alopecia Areata
Alopecia areata is an autoimmune disease that results in partial or complete loss of hair on the scalp and body that may affect up to 650,000 Americans at any given time. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both men and women Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of alopecia areata. In 2015, the FDA selected alopecia areata as one of eight new disease areas that it will focus on under its Patient-Focused Drug Development Initiative (PFDDI) meeting during fiscal year 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development.
Therapeutic Applications for Concert’s Partnered Programs
About Agitation in Alzheimer’s Disease
An estimated 6 million Americans have Alzheimer’s disease, a number that has doubled since 1980 and is expected to be as high as 16 million by 2050. Alzheimer’s disease is generally characterized by cognitive decline, impaired performance of daily activities, and behavioral disturbances. Behavioral and psychiatric symptoms develop in as many as 60 percent of community-dwelling dementia patients and in more than 80 percent of patients with dementia living in nursing homes. Dementia-related behavioral symptoms, including agitation, can be extremely distressing to the individual, the family and caregivers. These behavioral disturbances have been associated with more rapid cognitive decline, institutionalization and increased caregiver burden.
Schizophrenia is a chronic, severe, and disabling brain disorder. The symptoms of schizophrenia are marked by positive symptoms and negative symptoms. Positive symptoms are disturbances that are added to the person’s personality such as hallucinations and delusions. Negative symptoms are capabilities that are lost from the person’s personality such as social withdrawal, lack of drive or initiative or emotional unresponsiveness. Current antipsychotic medications provide some relief for the symptoms associated with the acute phase of the disorder, but they do not effectively treat the residual phase symptoms associated with chronic schizophrenia. According to the National Institute of Mental Health, about 1% of Americans have this illness.
Narcolepsy is a medical disorder that impacts 1 in approximately 2,000 people in the United States of America. The disease is a sleep disorder, involving irregular patterns in rapid eye movement (REM) sleep and significant disruptions of the normal sleep/wake cycle. While the cause of narcolepsy is not completely understood, current research points to a combination of genetic and environmental factors that influence the immune system.